Navigation Links
DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
Date:1/29/2009

EVRY, France, January 29 /PRNewswire/ -- DNA Therapeutics, an emerging biopharmaceutical company specialized in the development of innovat0ive medicines in oncology, announces the successful closing of its Series A equity investment round. The investor syndicate led by SGAM SEFTI with two of the previous seed investors, Blue Medical Investments and G1J-Ile de France, is committed to invest 2.2 million EUR based on certain milestones to be met. Since June 2008, DNA Therapeutics has raised 3 million EUR (US$4 million) through the current Series A and the previous seed financing round led by Inserm-Transfert Initiative.

The funds will enable DNA Therapeutics to advance the vectorization and the additional proofs of concept, and to achieve regulatory preclinical studies of its lead product, named Dbait. DNA Therapeutics is developing a new class of drugs fighting tumor resistance to conventional therapies. In current cancer treatment, the effectiveness of radiotherapy and chemotherapy are often limited by the action of DNA repair processes on the damages caused by these therapies. The innovative aspect of siDNA (signal interfering DNA) technology developed in DNA Therapeutics is to use a short fragment of DNA, a mimetic of DNA damage, to interfere with the sensing and signaling of DNA damages in the nucleus, and ultimately, inhibit their repair during the treatment period. Thus siDNA increases the effectiveness of radiotherapy and chemotherapy without adding any cytotoxic effect. The company possesses a portfolio of exclusive worldwide licenses resulting from the pioneering work of its founding scientists at the Institut Curie, the CNRS, the INSERM (French NIH) and the French National Museum of Natural History.

Prof. Jian-Sheng Sun, co-founder, Chairman and CEO commented: "We are delighted to have received this significant investment from SGAM SEFTI that is strongly committed to support Life Science innovati
'/>"/>

SOURCE DNA Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
2. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
3. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
7. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
8. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
9. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
10. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
11. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Mich. , Aug. 31, 2015  Diplomat Pharmacy, Inc. ... has announced that Phil Hagerman , Chairman & CEO, ... upcoming investor conferences. Mr. Hagerman and Mr. ... Healthcare Conference in Boston on Wednesday, ... Hagerman and Mr. Whelan are also scheduled to participate in ...
(Date:8/31/2015)... Aug. 31, 2015  Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today it has completed enrollment of the ... Committee (DRC) earlier this year, into the company,s ... first-in-class innate defense regulator (IDR) and is being ...
(Date:8/31/2015)... LAKE, N.J. and STAMFORD, Conn. ... U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue ... a worldwide collaboration agreement for the development and commercialization ... dual orexin receptor antagonist entering Phase III clinical development ... the terms of the agreement, Eisai and Purdue Pharma ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
... NEW YORK, Nov. 15, 2011 Reportlinker.com ... is available in its catalogue: ... East Asia ... analysis of four pharmaceutical markets that present ...
... SuccessEHS Director of Client Services Elizabeth Pharo will serve as ... This breakout session on Nov. 17 will highlight concrete examples ... have led to care improvements. The panel session is part ... Information Technology (ONC) Annual Meeting that will take place Nov. ...
Cached Medicine Technology:The Outlook for Pharmaceuticals in North East Asia 2The Outlook for Pharmaceuticals in North East Asia 3The Outlook for Pharmaceuticals in North East Asia 4SuccessEHS Director of Client Services to Serve as Panelist at ONC Annual Meeting 2SuccessEHS Director of Client Services to Serve as Panelist at ONC Annual Meeting 3
(Date:8/31/2015)... NEW YORK (PRWEB) , ... August 31, 2015 , ... ... for anti-aging products for men and barbershops are scrambling to meet it. , Reports ... get information for hairstyles and haircare. But the data also reflects that men are ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... for physicians and allied health professionals dedicated to using lifestyle as a ... the establishment of the Lifestyle Medicine Lifetime Achievement and Trailblazer Awards, with ...
(Date:8/31/2015)... ... August 31, 2015 , ... Westchester Insurance, a full service ... up with the Tarrant County chapter of Meals on Wheels to provide healthy ... oldest and largest national organization that supports the more than five thousand nutrition ...
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based ... with Bright Pink® to raise money and awareness for breast and ovarian health. ... Hot Pink Sassy incandescent Mood-lite sold to Bright Pink® to encourage households, dorms, ...
(Date:8/31/2015)... ... ... There’s big news for ZendyHealth , a Los Angeles-based startup company ... health plans (CDHPs) are a growing phenomenon, and ZendyHealth has brought on two experts ... another to answer customers’ questions directly. , John Young, CEO of Consumerdriven, LLC will ...
Breaking Medicine News(10 mins):Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 2Health News:MENAJI Anti-Aging Eraser a New Sure-Fire Add-On Product for Barbershops 3Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 3Health News:Westchester Insurance and the Meals on Wheels Association Announce Joint Charity Effort to Provide Nutritious Meals for Senior Citizens 2Health News:Westchester Insurance and the Meals on Wheels Association Announce Joint Charity Effort to Provide Nutritious Meals for Senior Citizens 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 3
... magazine has reported that cancer patients have been buying an untried ... illness//. The drug called DCA, short form for dichlroacetate has been ... has not been tested in humans so far. ,Understandably, ... in humans and it has been reported that around two hundred ...
... 29 (DPA) A Serbian patient has survived more than a ... Belgrade daily Blic reported Thursday.// ,The gauze was ... a spokesman of the Sremska Kamenica cardiovascular institute, 70 km ... ,It was found during surgery in mid-March. The latter operation ...
... millions of Americans whose vision is slowly ebbing due to ... may be riding to the rescue. ,In a ... stem cells have been shown to protect the vision of ... diseases that afflict humans. The new study appears today (March ...
... found mainly in partially hydrogenated vegetable oils and widely ... an increased risk of coronary heart disease (CHD). ... use in restaurants, and other cities are considering similar ... Public Health (HSPH) provides the strongest association to date ...
... Patricia Hewitt, the health secretary said that computer based ... depression and anxiety//. This will be available to all ... programs- Fear fighter and Beating the blues have been ... However, health experts have warned that computer aided programs ...
... can do more than making you look like one. It steers ... are a woman//, say researchers. , The report published ... by lead author Dr. David W. Dunstan and team from the ... data from people who confessed to sedentary lives ruled by lots ...
Cached Medicine News:Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 2Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 3Health News:Higher Trans Fat Levels in Blood Associated With Elevated Risk of Heart Disease 2Health News:Computer Based Therapy For Depression 2Health News:Sedentary Lives Equal Shorter ‘sweeter’ Liv 2
... a two chain (alpha- and beta-subunits) glycoprotein ... the placenta and is normally found in ... the trophoblastic epithelium of the placenta, hCG ... the early stages of pregnancy. The primary ...
... for movement is critical ... wheelchairs. Thats why this ... technology to do just ... state-of-the-art technology, these wheelchair ...
When patients are less mobile our ProPlus™ Stand-On Scale with built-in wheels moves easily to them. Extremely durable and safe, the easy grip handrail and non-skid platform provide added suppo...
... 100 provides a new screening, diagnostic, treatment ... medical management of sleep-related breathing disorders. The ... unmet need for an ambulatory, reliable, patient ... to the great number of OSA sufferers, ...
Medicine Products: